Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Total Non-Current Liabilities (2020 - 2024)

Historic Total Non-Current Liabilities for Puma Biotechnology (PBYI) over the last 6 years, with Q3 2025 value amounting to $87.6 million.

  • Puma Biotechnology's Total Non-Current Liabilities fell 4141.34% to $87.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $87.6 million, marking a year-over-year decrease of 4141.34%. This contributed to the annual value of $121.1 million for FY2024, which is 3157.57% down from last year.
  • According to the latest figures from Q3 2025, Puma Biotechnology's Total Non-Current Liabilities is $87.6 million, which was down 4141.34% from $90.2 million recorded in Q2 2025.
  • Puma Biotechnology's Total Non-Current Liabilities' 5-year high stood at $241.1 million during Q1 2021, with a 5-year trough of $87.6 million in Q3 2025.
  • Its 5-year average for Total Non-Current Liabilities is $168.3 million, with a median of $163.0 million in 2024.
  • In the last 5 years, Puma Biotechnology's Total Non-Current Liabilities skyrocketed by 174.3% in 2021 and then crashed by 4231.83% in 2025.
  • Over the past 5 years, Puma Biotechnology's Total Non-Current Liabilities (Quarter) stood at $228.1 million in 2021, then decreased by 15.37% to $193.1 million in 2022, then fell by 8.34% to $177.0 million in 2023, then crashed by 31.58% to $121.1 million in 2024, then decreased by 27.66% to $87.6 million in 2025.
  • Its last three reported values are $87.6 million in Q3 2025, $90.2 million for Q2 2025, and $99.1 million during Q1 2025.